JP2013531471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531471A5 JP2013531471A5 JP2013506330A JP2013506330A JP2013531471A5 JP 2013531471 A5 JP2013531471 A5 JP 2013531471A5 JP 2013506330 A JP2013506330 A JP 2013506330A JP 2013506330 A JP2013506330 A JP 2013506330A JP 2013531471 A5 JP2013531471 A5 JP 2013531471A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- raav
- administration
- cns
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003169 central nervous system Anatomy 0.000 claims 32
- 239000013598 vector Substances 0.000 claims 29
- 210000001519 tissue Anatomy 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 241000702421 Dependoparvovirus Species 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 108700019146 Transgenes Proteins 0.000 claims 12
- 108090000565 Capsid Proteins Proteins 0.000 claims 10
- 102100023321 Ceruloplasmin Human genes 0.000 claims 10
- 108091070501 miRNA Proteins 0.000 claims 9
- 239000002679 microRNA Substances 0.000 claims 9
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 8
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 8
- 102000036509 GTP Cyclohydrolase Human genes 0.000 claims 8
- 108010023555 GTP Cyclohydrolase Proteins 0.000 claims 8
- 241000699666 Mus <mouse, genus> Species 0.000 claims 8
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 8
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 8
- 229940053128 nerve growth factor Drugs 0.000 claims 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 241000700159 Rattus Species 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000002518 glial effect Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 4
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 4
- 208000022526 Canavan disease Diseases 0.000 claims 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 4
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 claims 4
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 239000000158 apoptosis inhibitor Substances 0.000 claims 4
- 108010046910 brain-derived growth factor Proteins 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 108091006086 inhibitor proteins Proteins 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000009223 neuronal apoptosis Effects 0.000 claims 4
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 3
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 3
- 241000282553 Macaca Species 0.000 claims 3
- 238000007914 intraventricular administration Methods 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 101100222092 Caenorhabditis elegans csp-3 gene Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 108010025815 Kanamycin Kinase Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 238000000185 intracerebroventricular administration Methods 0.000 claims 2
- 241001515942 marmosets Species 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 101800000263 Acidic protein Proteins 0.000 claims 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 claims 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 claims 1
- 108700023155 Aspartoacylases Proteins 0.000 claims 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 102000018919 aspartoacylase Human genes 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108091006047 fluorescent proteins Proteins 0.000 claims 1
- 102000034287 fluorescent proteins Human genes 0.000 claims 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 210000005230 lumbar spinal cord Anatomy 0.000 claims 1
- 210000004705 lumbosacral region Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000004129 prosencephalon Anatomy 0.000 claims 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 claims 1
- 239000013608 rAAV vector Substances 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000001103 thalamus Anatomy 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32762710P | 2010-04-23 | 2010-04-23 | |
| US61/327,627 | 2010-04-23 | ||
| PCT/US2011/033616 WO2011133890A1 (en) | 2010-04-23 | 2011-04-22 | Cns targeting aav vectors and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000310A Division JP6235619B2 (ja) | 2010-04-23 | 2016-01-04 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2016000309A Division JP6422897B2 (ja) | 2010-04-23 | 2016-01-04 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531471A JP2013531471A (ja) | 2013-08-08 |
| JP2013531471A5 true JP2013531471A5 (enExample) | 2014-08-21 |
| JP5963743B2 JP5963743B2 (ja) | 2016-08-03 |
Family
ID=44834531
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013506330A Active JP5963743B2 (ja) | 2010-04-23 | 2011-04-22 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2016000310A Active JP6235619B2 (ja) | 2010-04-23 | 2016-01-04 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2016000309A Active JP6422897B2 (ja) | 2010-04-23 | 2016-01-04 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2018195573A Active JP6879988B2 (ja) | 2010-04-23 | 2018-10-17 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2019005016A Active JP6941632B2 (ja) | 2010-04-23 | 2019-01-16 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2021077161A Pending JP2021138702A (ja) | 2010-04-23 | 2021-04-30 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000310A Active JP6235619B2 (ja) | 2010-04-23 | 2016-01-04 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2016000309A Active JP6422897B2 (ja) | 2010-04-23 | 2016-01-04 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2018195573A Active JP6879988B2 (ja) | 2010-04-23 | 2018-10-17 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2019005016A Active JP6941632B2 (ja) | 2010-04-23 | 2019-01-16 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
| JP2021077161A Pending JP2021138702A (ja) | 2010-04-23 | 2021-04-30 | Ｃｎｓターゲティングａａｖベクターおよびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (8) | US9102949B2 (enExample) |
| EP (6) | EP2826860B1 (enExample) |
| JP (6) | JP5963743B2 (enExample) |
| CA (3) | CA3049237C (enExample) |
| DK (2) | DK2826860T3 (enExample) |
| ES (2) | ES2698203T3 (enExample) |
| WO (1) | WO2011133890A1 (enExample) |
Families Citing this family (230)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103555677B (zh) | 2001-11-13 | 2018-01-30 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| EP2018421B1 (en) | 2006-04-28 | 2012-12-19 | The Trustees of the University of Pennsylvania | Scalable production method for aav |
| EP2623605B1 (en) | 2007-04-09 | 2018-11-28 | University of Florida Research Foundation, Inc. | RAAV vector compositions having tyrosine-modified capsid proteins and methods for use |
| US9725485B2 (en) * | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| CA2833905C (en) | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
| EP2561075B1 (en) | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| DK2826860T3 (en) * | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
| EP3318634A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations |
| US20130039888A1 (en) | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
| US10815285B2 (en) * | 2011-07-01 | 2020-10-27 | University Of South Florida | Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases |
| WO2013123503A1 (en) * | 2012-02-17 | 2013-08-22 | The Children's Hospital Of Philadelphia | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| US12358954B2 (en) | 2012-05-15 | 2025-07-15 | University Of Florida Research Foundation, Incorporated | Capsid-modified rAAV vector compositions and methods therefor |
| EP2855684A1 (en) * | 2012-05-25 | 2015-04-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Vector for the selective silencing of a gene in astrocytes |
| WO2013190059A1 (en) * | 2012-06-21 | 2013-12-27 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
| EP2879719B1 (en) | 2012-08-01 | 2018-07-04 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| US12024568B2 (en) * | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| JP2015529685A (ja) | 2012-09-17 | 2015-10-08 | ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ | 筋萎縮性側索硬化症の処置のための組成物および方法 |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| DK2956477T4 (da) | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
| EP2970946A4 (en) * | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| EP3533393B1 (en) | 2013-03-14 | 2020-07-22 | Universite Laval | Use of electroretinography (erg) for the assessment of psychiatric disorders |
| SG10201707319UA (en) | 2013-03-15 | 2017-10-30 | Univ Pennsylvania | Compositions and methods for treating mpsi |
| CA2912678C (en) * | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| CA3209883A1 (en) | 2013-07-22 | 2015-01-29 | The Children's Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| BR112016001592A2 (pt) * | 2013-07-26 | 2017-11-28 | Univ Iowa Res Found | métodos e composições para o tratamento de doenças cerebrais |
| LT3702466T (lt) | 2013-08-27 | 2023-02-27 | Research Institute At Nationwide Children's Hospital | Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| CN105745326A (zh) * | 2013-10-24 | 2016-07-06 | 优尼科Ip有限公司 | 用于基因治疗神经疾病的aav-5假型载体 |
| JP2016538276A (ja) | 2013-11-05 | 2016-12-08 | ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔ Ｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ | 筋萎縮性側索硬化症の処置のためのＮＦ−κＢおよびＳＯＤ−１を阻害する組成物および方法 |
| JP6567974B2 (ja) | 2013-11-29 | 2019-08-28 | タカラバイオ株式会社 | アデノ随伴ウイルスの定量方法 |
| AU2014362722B2 (en) * | 2013-12-11 | 2021-06-10 | Riken | Method for manufacturing ciliary marginal zone-like structure |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
| AU2015231294B2 (en) | 2014-03-18 | 2020-10-29 | University Of Massachusetts | rAAV-based compositions and methods for treating amyotrophic lateral sclerosis |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| WO2015164723A1 (en) * | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| WO2015168666A2 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EP3795580A1 (en) | 2014-10-03 | 2021-03-24 | University of Massachusetts | High efficiency library-identified aav vectors |
| WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| WO2016065001A1 (en) * | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
| CN112553229A (zh) | 2014-11-05 | 2021-03-26 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| BR112017010447A2 (pt) * | 2014-11-21 | 2018-05-15 | The University Of North Carolina At Chapel Hill | vetores de aav direcionados ao sistema nervoso central |
| EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| CN107249646B (zh) | 2014-12-16 | 2021-06-29 | 内布拉斯加大学董事会 | 用于青少年巴滕病的基因疗法 |
| US20180030096A1 (en) | 2015-02-03 | 2018-02-01 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
| SG11201706444TA (en) | 2015-02-10 | 2017-09-28 | Genzyme Corp | VARIANT RNAi |
| US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| JP2018509164A (ja) * | 2015-03-10 | 2018-04-05 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 組換えＧｌｕｔ１アデノ随伴ウイルスベクターコンストラクトおよびＧｌｕｔ１発現を回復させる方法 |
| CA3021949C (en) | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Modified aav constructs and uses thereof |
| US20170067028A1 (en) * | 2015-05-15 | 2017-03-09 | Douglas J. Ballon | Radiolabeling of adeno associated virus |
| RU2021134920A (ru) * | 2015-05-29 | 2022-04-15 | Дзе Трастиз Оф Дзе Юнивёрсити Оф Пенсильвания | Композиции и способы деградации неправильно упакованных белков |
| HUE068603T2 (hu) | 2015-06-23 | 2025-01-28 | Childrens Hospital Philadelphia | Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez |
| US10801040B2 (en) | 2015-07-07 | 2020-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject |
| US10047377B2 (en) * | 2015-09-22 | 2018-08-14 | Loyola University Of Chicago | Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor |
| US10597655B2 (en) * | 2015-09-22 | 2020-03-24 | Loyola University Chicago | Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor |
| JP7064214B2 (ja) | 2015-09-28 | 2022-05-10 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 抗体回避性ウイルスベクターのための方法および組成物 |
| WO2017060510A1 (en) * | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of alzheimer's disease |
| US11426469B2 (en) | 2015-10-22 | 2022-08-30 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
| CN105420275A (zh) * | 2015-11-27 | 2016-03-23 | 中国科学院苏州生物医学工程技术研究所 | 制备外源功能基因定点整合的人神经干细胞的方法 |
| AU2016362477A1 (en) | 2015-12-02 | 2018-06-14 | Voyager Therapeutics, Inc. | Assays for the detection of AAV neutralizing antibodies |
| DK3387137T3 (da) | 2015-12-11 | 2021-05-03 | California Inst Of Techn | Målretningspeptider til styring af adeno-associerede virusser (aav`er) |
| EP3387118B1 (en) | 2015-12-11 | 2022-04-06 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aavrh10 |
| US11015173B2 (en) | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV1 |
| US11098286B2 (en) | 2015-12-11 | 2021-08-24 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV9 |
| WO2017100676A1 (en) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav8 |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| EP3411059A4 (en) | 2016-02-02 | 2019-10-16 | University Of Massachusetts | METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM |
| WO2017136500A1 (en) | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| EP3413928B1 (en) * | 2016-02-12 | 2022-04-20 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| MX394648B (es) * | 2016-03-31 | 2025-03-24 | Univ Cincinnati | Composiciones que contienen vectores modificados de virus adeno-asociados para usarse en el tratamiento de esclerosis lateral amiotrófica. |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| WO2017181105A1 (en) | 2016-04-15 | 2017-10-19 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| WO2017181113A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| GB201608046D0 (en) | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| CN116333057A (zh) | 2016-05-13 | 2023-06-27 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和其使用方法 |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics, Inc. | composições e métodos de tratamento da doença de huntington |
| WO2017218852A1 (en) | 2016-06-15 | 2017-12-21 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| KR102621134B1 (ko) * | 2016-07-26 | 2024-01-04 | 코넬 유니버시티 | 알데히드 데히드로게나제 결핍의 치료를 위한 유전자 요법 |
| US11698377B2 (en) | 2016-08-15 | 2023-07-11 | Genzyme Corporation | Methods for detecting AAV |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| WO2018064098A1 (en) | 2016-09-28 | 2018-04-05 | Cohbar, Inc. | Therapeutic mots-c related peptides |
| CN116554320A (zh) | 2016-10-12 | 2023-08-08 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
| IL266358B2 (en) | 2016-11-09 | 2025-10-01 | Precigen Inc | Constructs for Prataxin Expression |
| WO2018156892A1 (en) | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| CA3058189A1 (en) | 2017-04-03 | 2018-10-11 | Encoded Therapeutics, Inc. | Tissue selective transgene expression |
| WO2018191450A2 (en) | 2017-04-14 | 2018-10-18 | National Taiwan University Hospital | Gene therapy for aadc deficiency |
| CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP3622073A4 (en) | 2017-05-09 | 2021-01-06 | University of Massachusetts | METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3634978A1 (en) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau aggregation inhibitors |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| AU2018298133A1 (en) | 2017-07-06 | 2020-01-23 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
| BR112020005436B1 (pt) | 2017-09-20 | 2022-08-02 | 4D Molecular Therapeutics Inc | Proteína do capsídeo de variante do vírus adenoassociado, virion do aav recombinante (raav) infeccioso, composições, composições farmacêuticas e usos de virion de raav ou de composições farmacêuticas |
| WO2019060662A1 (en) | 2017-09-22 | 2019-03-28 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II |
| MY205041A (en) | 2017-09-22 | 2024-09-29 | Genzyme Corp | Variant rnai |
| JP7397488B2 (ja) | 2017-09-22 | 2023-12-13 | ユニバーシティ オブ マサチューセッツ | Ｓｏｄ１二重発現ベクターおよびその使用 |
| AU2018338728B2 (en) * | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| MA49923A (fr) * | 2017-10-02 | 2020-06-24 | Res Inst Nationwide Childrens Hospital | Système de déciblage de miarn pour interférence spécifique d'un tissu |
| WO2019070891A1 (en) | 2017-10-03 | 2019-04-11 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISORDERS |
| KR102700963B1 (ko) | 2017-10-03 | 2024-09-02 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| IL278868B2 (en) | 2017-10-03 | 2025-06-01 | Prevail Therapeutics Inc | Gene therapies for lysosomal disorders |
| US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
| US12441998B2 (en) * | 2017-10-12 | 2025-10-14 | The Trustees Of Columbia University In The City Of New York | SLC2A1 lncRNA as a biologic and related treatments and methods |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| FI3717636T3 (fi) | 2017-11-27 | 2023-06-01 | 4D Molecular Therapeutics Inc | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä |
| JP7389744B2 (ja) | 2017-11-30 | 2023-11-30 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ｉｉｉａ型のための遺伝子療法 |
| CN111989396A (zh) | 2017-11-30 | 2020-11-24 | 宾夕法尼亚州大学信托人 | 用于iiib型粘多糖贮积病的基因疗法 |
| SG11202004926WA (en) | 2017-12-01 | 2020-06-29 | Encoded Therapeutics Inc | Engineered dna binding proteins |
| KR20200135433A (ko) * | 2018-03-23 | 2020-12-02 | 유니버시티 오브 매사추세츠 | 골 장애 치료를 위한 유전자 치료제 |
| US12091435B2 (en) | 2018-04-03 | 2024-09-17 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| JP7425738B2 (ja) | 2018-04-03 | 2024-01-31 | ギンコ バイオワークス インコーポレイテッド | 眼組織を標的とするウイルスベクター |
| MX2020010464A (es) | 2018-04-03 | 2021-01-29 | Vectores de virus que evitan anticuerpos. | |
| US12054724B2 (en) | 2018-04-10 | 2024-08-06 | President And Fellows Of Harvard College | AAV vectors encoding clarin-1 or GJB2 and uses thereof |
| US12460226B2 (en) | 2018-04-16 | 2025-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating duchenne muscular dystrophy |
| WO2019210137A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
| AU2019268330A1 (en) | 2018-05-15 | 2020-11-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒（ａａｖ）之組成物和方法 |
| US12163129B2 (en) | 2018-06-08 | 2024-12-10 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| US12060567B2 (en) | 2018-06-13 | 2024-08-13 | Voyager Therapeutics, Inc. | Engineered untranslated regions (UTR) for AAV production |
| US12297241B2 (en) | 2018-07-06 | 2025-05-13 | The Regents Of The University Of California | Method to engineer transplantable human tissues |
| CN120843603A (zh) * | 2018-07-11 | 2025-10-28 | 布里格姆妇女医院 | 用于跨血脑屏障递送试剂的方法和组合物 |
| MX2021000810A (es) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Sistemas y metodos para producir formulaciones de terapia genetica. |
| EA202190358A1 (ru) * | 2018-07-31 | 2021-05-04 | Корнелл Юниверсити | Способы генной терапии для контроля функции органов |
| MX2021001395A (es) | 2018-08-03 | 2021-08-11 | Genzyme Corp | Arni variante contra alfa-sinucleína. |
| EP3830107A2 (en) | 2018-08-03 | 2021-06-09 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| AU2019328337B2 (en) * | 2018-08-30 | 2025-04-17 | Rowan University | Methods of treating or preventing amyotrophic lateral sclerosis |
| CN113966399A (zh) | 2018-09-26 | 2022-01-21 | 加州理工学院 | 用于靶向基因疗法的腺相关病毒组合物 |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN119684417A (zh) | 2018-10-02 | 2025-03-25 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CN113166781A (zh) | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
| MX2021006646A (es) * | 2018-12-05 | 2021-12-10 | Abeona Therapeutics Inc | Vector viral adenoasociado recombinante para el suministro de genes. |
| PE20211581A1 (es) * | 2018-12-21 | 2021-08-17 | Univ Pennsylvania | Composiciones para la reduccion de la expresion transgenica especifica de drg |
| KR20210121132A (ko) | 2019-01-28 | 2021-10-07 | 코바, 인크. | 치료용 펩티드 |
| BR112021016501A2 (pt) | 2019-02-25 | 2021-10-26 | Novartis Ag | Composições e métodos para tratar distrofia cristalina de bietti |
| US20220154211A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| EP3935078A4 (en) | 2019-03-04 | 2022-12-21 | Duke University | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF RETINOPATHIES |
| JP7698583B2 (ja) | 2019-03-21 | 2025-06-25 | ギンコ バイオワークス インコーポレイテッド | 組換えアデノ随伴ウイルスベクター |
| KR20210149803A (ko) | 2019-04-10 | 2021-12-09 | 유니버시티 오브 매사추세츠 | 인자 h 벡터 및 그의 용도 |
| MX2021012184A (es) | 2019-04-10 | 2022-01-24 | Prevail Therapeutics Inc | Terapias genicas para trastornos lisosomales. |
| WO2020210592A1 (en) * | 2019-04-12 | 2020-10-15 | University Of Massachusetts | Recombinant aav gene therapy for ngyl1 deficiency |
| US20220243225A1 (en) | 2019-04-29 | 2022-08-04 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| US12516351B2 (en) * | 2019-04-29 | 2026-01-06 | The Trustees Of The University Of Pennsylvania | AAV capsids and compositions containing same |
| WO2020223280A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| BR112021024055A2 (pt) | 2019-05-29 | 2022-02-08 | Encoded Therapeutics Inc | Composições e métodos para a regulação seletiva de gene |
| KR20220016100A (ko) * | 2019-05-31 | 2022-02-08 | 유니버시타트 아우토노마 데 바르셀로나 | 인슐린 유전자 요법 |
| EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
| US11446084B2 (en) | 2019-07-12 | 2022-09-20 | Neuralink Corp. | Laser drilling of pia mater |
| US20220281922A1 (en) | 2019-08-02 | 2022-09-08 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| GB2587319A (en) * | 2019-08-12 | 2021-03-31 | Healing Genes Llc | Genetic construct |
| EP4022070A1 (en) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| JP2022545534A (ja) * | 2019-08-29 | 2022-10-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ヒト血液脳関門を通過するためのアデノ随伴ウイルスベクター |
| US20220333133A1 (en) | 2019-09-03 | 2022-10-20 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| IL292297A (en) * | 2019-10-17 | 2022-06-01 | Stridebio Inc | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| CN113614225A (zh) * | 2019-12-17 | 2021-11-05 | 耐克基因有限责任公司 | 细小病毒载体及其制备方法和用途 |
| CN115279400A (zh) * | 2020-01-10 | 2022-11-01 | 布里格姆妇女医院 | 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物 |
| BR112022014852A2 (pt) | 2020-01-29 | 2022-10-11 | Genzyme Corp | Proteínas modificadas do capsídeo viral adenoassociado para terapia gênica ocular e métodos de uso das mesmas |
| US12442017B2 (en) | 2020-03-02 | 2025-10-14 | National University Corporation Gunma University | Microglial selective gene expression vector |
| WO2021189144A1 (en) | 2020-03-26 | 2021-09-30 | Diamentis Inc. | Systems and methods for processing retinal signal data and identifying conditions |
| EP4135841A1 (en) | 2020-04-15 | 2023-02-22 | Voyager Therapeutics, Inc. | Tau binding compounds |
| GB202005732D0 (en) * | 2020-04-20 | 2020-06-03 | Synpromics Ltd | Regulatory nucleic acid sequences |
| IL297605A (en) * | 2020-04-28 | 2022-12-01 | Pfizer | Modified nucleic acids encoding aspartoacylase (aspa) and vector for gene therapy |
| EP4162059A1 (en) | 2020-05-12 | 2023-04-12 | The Trustees of The University of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| IL298001A (en) | 2020-05-13 | 2023-01-01 | Voyager Therapeutics Inc | Redirecting tropism of adeno-associated virus capsids |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| WO2021262963A1 (en) | 2020-06-24 | 2021-12-30 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein |
| GB202010981D0 (en) | 2020-07-16 | 2020-09-02 | Ucl Business Ltd | Gene therapy for neuromuscular and neuromotor disorders |
| EP4192518A4 (en) * | 2020-08-05 | 2024-12-25 | Hangzhou Exegenesis Bio Ltd. | NUCLEIC ACID CONSTRUCTS AND THEIR USES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| CA3189878A1 (en) | 2020-08-19 | 2022-02-24 | Colin O'BANION | Adeno-associated virus vectors for treatment of rett syndrome |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| WO2022096092A1 (en) * | 2020-11-04 | 2022-05-12 | Boehringer Ingelheim International Gmbh | Viral vectors and nucleic acids for use in the treatment of ild, pf-ild and ipf |
| US20240050593A1 (en) * | 2020-12-18 | 2024-02-15 | Duke University | Compositions For and Methods of Enhancing Spinal Cord Tissue Regeneration |
| EP4301768A2 (en) | 2021-03-03 | 2024-01-10 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022192708A1 (en) * | 2021-03-11 | 2022-09-15 | Temple University- Of The Commonwealth System Of Higher Education | Noninvasive aav vectors for highly efficient gene delivery to the nervous system |
| CN117157309A (zh) | 2021-05-28 | 2023-12-01 | 上海瑞宏迪医药有限公司 | 衣壳变异的重组腺相关病毒及其应用 |
| US20250001008A1 (en) * | 2021-07-01 | 2025-01-02 | Bridgebio Gene Therapy Research, Inc. | Gene therapy for galactosemia |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| JP2024539012A (ja) | 2021-10-12 | 2024-10-28 | ブリッジバイオ ジーン セラピー エルエルシー | 白質ジストロフィーを治療するための方法及び組成物 |
| WO2023081648A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| US20250295807A1 (en) | 2021-11-15 | 2025-09-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| EP4442830A4 (en) | 2021-11-29 | 2025-04-30 | Shanghai Regenelead Therapies Co., Ltd. | AADC/GDNF polynucleotide and use thereof in the treatment of Parkinson's disease |
| US20250346920A1 (en) | 2022-01-25 | 2025-11-13 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| IL314676A (en) | 2022-02-09 | 2024-10-01 | Diamentis Inc | Systems and methods for retinal stimulation and/or retinal signal data collection |
| AU2023220237A1 (en) | 2022-02-21 | 2024-08-15 | Shanghai Regenelead Therapies Co., Ltd | Vegf-binding molecule and pharmaceutical use thereof |
| KR20250004740A (ko) | 2022-04-12 | 2025-01-08 | 젠자임 코포레이션 | 유전자 요법을 위한 irak4 조절제의 용도 |
| AU2023253700A1 (en) | 2022-04-12 | 2024-11-28 | Genzyme Corporation | Use of an irak4 modulator for gene therapy |
| JP2025512400A (ja) | 2022-04-12 | 2025-04-17 | ジェンザイム・コーポレーション | 遺伝子治療剤に対する自然免疫原性のための樹状細胞アッセイ |
| EP4511498A1 (en) * | 2022-04-22 | 2025-02-26 | The Children's Hospital of Philadelphia | Human ependyma-specific promoter and uses thereof |
| EP4522757A2 (en) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2024027632A1 (en) * | 2022-08-01 | 2024-02-08 | Skyline Therapeutics (Shanghai) Co., Ltd. | Novel plasmid backbone to reduce dna impurities in raav preparation |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| GB2622629A (en) | 2022-09-23 | 2024-03-27 | Sania Rx Ltd | Method |
| WO2025128817A1 (en) | 2023-12-15 | 2025-06-19 | Genzyme Corporation | Artificial micrornas targeting tau |
| WO2025158385A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
| TW202548014A (zh) | 2024-01-26 | 2025-12-16 | 美商健臻公司 | 靶向亨丁頓舞蹈症之人工ｍｉｃｒｏｒｎａ |
| WO2025160429A1 (en) | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting snca |
| GB202406331D0 (en) | 2024-05-07 | 2024-06-19 | Sania Rx Ltd | Capsid |
| WO2025235643A1 (en) | 2024-05-08 | 2025-11-13 | Genzyme Corporation | Profiling of gene therapy agents |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043270A (en) | 1989-03-31 | 1991-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | Intronic overexpression vectors |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| WO1995028493A1 (en) | 1994-04-13 | 1995-10-26 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5697899A (en) | 1995-02-07 | 1997-12-16 | Gensia | Feedback controlled drug delivery system |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| US5779708A (en) | 1996-08-15 | 1998-07-14 | Cyberdent, Inc. | Intraosseous drug delivery device and method |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6177403B1 (en) | 1996-10-21 | 2001-01-23 | The Trustees Of The University Of Pennsylvania | Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US6475469B1 (en) | 1996-11-21 | 2002-11-05 | Applied Dental Sciences, Inc. | Compositions for removing tooth stains |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6251677B1 (en) | 1997-08-25 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
| EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
| US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| JP2002528049A (ja) | 1998-07-22 | 2002-09-03 | イミューソル インコーポレイテッド | 実質的に完全なリボザイムライブラリー |
| US20030110526A1 (en) | 1998-08-25 | 2003-06-12 | Robert H. Brown | Dysferlin mutations |
| JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
| US6498244B1 (en) | 1999-05-28 | 2002-12-24 | Cell Genesys, Inc. | Adeno-associated virus capsid immunologic determinants |
| US6365394B1 (en) | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| AU7895700A (en) | 1999-10-15 | 2001-04-30 | Dalhousie University | Method and vector for producing and transferring trans-spliced peptides |
| US6821512B1 (en) | 1999-12-03 | 2004-11-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for increasing packaging and yield of recombinant adenoviruses using multiple packaging signals |
| US7638120B2 (en) | 2000-03-14 | 2009-12-29 | Thomas Jefferson University | High transgene expression of a pseudotyped adeno-associated virus type |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| ATE530672T1 (de) | 2001-06-22 | 2011-11-15 | Univ Pennsylvania | Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon. |
| US20040136963A1 (en) | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| WO2003004660A1 (en) * | 2001-07-03 | 2003-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods of administering vectors to synaptically connected neurons |
| EP1419245A4 (en) | 2001-07-13 | 2006-04-05 | Univ Iowa Res Found | ADENO-ASSOCIATED PSEUDOTYPE VIRUSES AND USES THEREOF |
| US20030092161A1 (en) | 2001-09-19 | 2003-05-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for production of recombinant viruses, and uses therefor |
| CN103555677B (zh) | 2001-11-13 | 2018-01-30 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| HU230364B1 (hu) | 2001-11-21 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására |
| PT2573170T (pt) | 2001-12-17 | 2018-03-26 | Univ Pennsylvania | Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações |
| WO2003052051A2 (en) | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
| US20050137153A1 (en) | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
| WO2003089612A2 (en) | 2002-04-17 | 2003-10-30 | University Of Florida Research Foundation, Inc. | IMPROVED rAAV VECTORS |
| US20070003518A1 (en) | 2002-04-19 | 2007-01-04 | Atkinson Mark A | Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases |
| CA2426283C (en) | 2002-04-29 | 2006-06-27 | The Trustees Of The University Of Pennsylvania | Method for direct rescue and amplification of integrated viruses from cellular dna of tissues |
| US20060093589A1 (en) | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
| US7387896B2 (en) | 2003-03-26 | 2008-06-17 | The Regents Of The University Of Michigan | MicroRNA vectors |
| US20060228800A1 (en) | 2003-05-15 | 2006-10-12 | Shi-Lung Lin | Novel Transgenic Methods Using intronic RNA |
| US7459547B2 (en) | 2003-06-02 | 2008-12-02 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
| DK3211085T3 (da) | 2003-09-30 | 2021-06-21 | Univ Pennsylvania | Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf |
| WO2005087926A2 (en) | 2004-03-05 | 2005-09-22 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| WO2005096781A2 (en) * | 2004-04-06 | 2005-10-20 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using rna interference |
| WO2005116224A2 (en) * | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| WO2006084209A2 (en) | 2005-02-03 | 2006-08-10 | Benitec, Inc. | Rnai expression constructs |
| EP1877556B1 (en) * | 2005-03-25 | 2011-09-14 | Medtronic, Inc. | Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain |
| US8999678B2 (en) | 2005-04-07 | 2015-04-07 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an AAV vector |
| US20100196335A1 (en) * | 2005-04-29 | 2010-08-05 | Samulski Richard J | Methods and Compositions for Regulated Expressions of Nucleic Acid at Post-Transcriptional Level |
| WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| SG162726A1 (en) * | 2005-05-27 | 2010-07-29 | San Raffaele Centro Fond | Gene vector comprising mi-rna |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2008016391A2 (en) | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| EP1986661B1 (en) * | 2006-02-08 | 2018-08-29 | Genzyme Corporation | Gene therapy for niemann-pick disease type a |
| CA2642848C (en) * | 2006-03-03 | 2016-07-12 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| EP2018421B1 (en) | 2006-04-28 | 2012-12-19 | The Trustees of the University of Pennsylvania | Scalable production method for aav |
| EP2799547B1 (en) | 2006-11-08 | 2016-12-21 | Veritas Bio, LLC | In Vivo Delivery of RNA to a Target Cell |
| CA2713977A1 (en) | 2007-02-15 | 2008-08-21 | National Jewish Medical And Research Center | Methods and compositions for the disruption of biofilms |
| EP2623605B1 (en) | 2007-04-09 | 2018-11-28 | University of Florida Research Foundation, Inc. | RAAV vector compositions having tyrosine-modified capsid proteins and methods for use |
| ES2907452T3 (es) | 2007-04-12 | 2022-04-25 | The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T | Supresión y reemplazo genético |
| EP2152890A1 (en) | 2007-05-23 | 2010-02-17 | MannKind Corporation | Multicistronic vectors and methods for their design |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| PT2164967E (pt) | 2007-05-31 | 2015-10-27 | Univ Iowa Res Found | Redução da toxicidade não dirigida do arn de interferência |
| PT3252161T (pt) | 2007-06-06 | 2022-02-01 | Genzyme Corp | Terapia genética para doenças do armazenamento lisossomal |
| EP2019143A1 (en) * | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| WO2009079592A2 (en) | 2007-12-17 | 2009-06-25 | California Institute Of Technology | Modulating immune system development and function through microrna mir-146 |
| US20090215879A1 (en) * | 2008-02-26 | 2009-08-27 | University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| WO2009146178A1 (en) * | 2008-04-15 | 2009-12-03 | President And Fellows Of Harvard College | Angiogenin and amyotrophic lateral sclerosis |
| DK2282764T3 (da) | 2008-04-22 | 2019-10-14 | Vib Vzw | Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| CA2726052A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| US20110171262A1 (en) | 2008-06-17 | 2011-07-14 | Andrew Christian Bakker | Parvoviral capsid with incorporated gly-ala repeat region |
| US20110172293A1 (en) | 2008-07-08 | 2011-07-14 | Fish Jason E | Methods and Compositions for Modulating Angiogenesis |
| WO2010034314A1 (en) | 2008-09-24 | 2010-04-01 | Aarhus Universitet | Retroviral delivery of synthectic gene cassettes |
| WO2010071454A1 (en) * | 2008-12-17 | 2010-06-24 | Auckland Uniservices Limited | Adeno-associated viral vectors and uses thereof |
| WO2010099383A2 (en) | 2009-02-26 | 2010-09-02 | The Johns Hopkins University | Compositions and methods for ex vivo hepatic nucleic acid delivery |
| SG10202109219SA (en) * | 2009-05-02 | 2021-10-28 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US20120270930A1 (en) | 2009-10-29 | 2012-10-25 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Methods and compositions for dysferlin exon-skipping |
| RU2606012C2 (ru) | 2009-11-09 | 2017-01-10 | Дженепод Терапевтикс Аб | Новая вирусная векторная конструкция для нейронспецифического оптимизированного непрерывного синтеза dopa in vivo |
| WO2011062298A1 (ja) | 2009-11-19 | 2011-05-26 | 国立大学法人岡山大学 | 遺伝子発現を上昇させるシステム及び該システムを保持したベクター |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011094198A1 (en) | 2010-01-28 | 2011-08-04 | The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| AU2011223820B2 (en) | 2010-03-01 | 2016-01-14 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the HCV genome |
| CA2833905C (en) | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
| EP2561075B1 (en) | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
| US8785413B2 (en) | 2010-09-27 | 2014-07-22 | Florida Atlantic University Research Corporation | Materials and methods for the treatment of pathological neovascularization in the eye |
| ES2739804T3 (es) | 2011-02-12 | 2020-02-04 | Univ Iowa Res Found | Compuestos terapéuticos |
| ES2724800T3 (es) | 2011-02-17 | 2019-09-16 | Univ Pennsylvania | Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9 |
| US20140147418A1 (en) | 2011-04-15 | 2014-05-29 | The Us Of America, As Represented By The Secretary Department Of Health And Human Services | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome |
| EP3318634A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations |
| US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
| US10184151B2 (en) | 2011-10-11 | 2019-01-22 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| US20130142861A1 (en) | 2011-12-05 | 2013-06-06 | National Yang Ming University | Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis |
| WO2013123503A1 (en) | 2012-02-17 | 2013-08-22 | The Children's Hospital Of Philadelphia | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| WO2013190059A1 (en) | 2012-06-21 | 2013-12-27 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
| JP2016507228A (ja) | 2013-01-14 | 2016-03-10 | リコンビネティクス・インコーポレイテッドＲｅｃｏｍｂｉｎｅｔｉｃｓ，Ｉｎｃ． | 無角家畜 |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| CN105163764B (zh) | 2013-03-15 | 2019-11-12 | 北卡罗来纳-查佩尔山大学 | 双重聚糖结合aav载体的方法和组合物 |
| ES2704677T3 (es) | 2013-04-18 | 2019-03-19 | Fond Telethon | Suministro eficaz de genes grandes por vectores de AAV duales |
| KR20240172759A (ko) | 2013-06-17 | 2024-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도 |
| WO2015009575A1 (en) | 2013-07-16 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of disorders related to cep290 |
| EP3030665B9 (en) | 2013-08-05 | 2023-10-04 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp |
| LT3702466T (lt) | 2013-08-27 | 2023-02-27 | Research Institute At Nationwide Children's Hospital | Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui |
| GB201401707D0 (en) | 2014-01-31 | 2014-03-19 | Sec Dep For Health The | Adeno-associated viral vectors |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| WO2015150922A2 (en) | 2014-03-17 | 2015-10-08 | The Hospital For Sick Children | β-HEXOSAMINIDASE PROTEIN VARIANTS AND ASSOCIATED METHODS FOR TREATING GM2 GANGLIOSIDOSES |
| AU2015231294B2 (en) | 2014-03-18 | 2020-10-29 | University Of Massachusetts | rAAV-based compositions and methods for treating amyotrophic lateral sclerosis |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| WO2015168666A2 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
| JP6663859B2 (ja) | 2014-05-20 | 2020-03-13 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | ハンチントン病の治療化合物 |
| WO2016065001A1 (en) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
| US20190000940A1 (en) | 2015-07-31 | 2019-01-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of aadc deficiency |
-
2011
- 2011-04-22 DK DK14181861.7T patent/DK2826860T3/en active
- 2011-04-22 CA CA3049237A patent/CA3049237C/en active Active
- 2011-04-22 EP EP14181861.7A patent/EP2826860B1/en active Active
- 2011-04-22 CA CA3066596A patent/CA3066596A1/en active Pending
- 2011-04-22 JP JP2013506330A patent/JP5963743B2/ja active Active
- 2011-04-22 WO PCT/US2011/033616 patent/WO2011133890A1/en not_active Ceased
- 2011-04-22 DK DK11772784.2T patent/DK2561073T3/en active
- 2011-04-22 EP EP11772784.2A patent/EP2561073B1/en active Active
- 2011-04-22 CA CA2833908A patent/CA2833908C/en active Active
- 2011-04-22 US US13/642,719 patent/US9102949B2/en active Active
- 2011-04-22 EP EP19166281.6A patent/EP3540055A1/en active Pending
- 2011-04-22 EP EP18248250.5A patent/EP3567106A1/en not_active Withdrawn
- 2011-04-22 ES ES14181861T patent/ES2698203T3/es active Active
- 2011-04-22 EP EP18190083.8A patent/EP3536781A1/en active Pending
- 2011-04-22 EP EP18248259.6A patent/EP3514232A1/en not_active Withdrawn
- 2011-04-22 ES ES11772784.2T patent/ES2605305T3/es active Active
-
2014
- 2014-07-29 US US14/445,670 patent/US9701984B2/en active Active
-
2016
- 2016-01-04 JP JP2016000310A patent/JP6235619B2/ja active Active
- 2016-01-04 JP JP2016000309A patent/JP6422897B2/ja active Active
-
2017
- 2017-06-05 US US15/613,646 patent/US10731178B2/en active Active
-
2018
- 2018-10-17 JP JP2018195573A patent/JP6879988B2/ja active Active
- 2018-12-28 US US16/234,834 patent/US20190194689A1/en not_active Abandoned
- 2018-12-28 US US16/234,819 patent/US20190194688A1/en not_active Abandoned
-
2019
- 2019-01-16 JP JP2019005016A patent/JP6941632B2/ja active Active
- 2019-03-26 US US16/365,065 patent/US20190276849A1/en not_active Abandoned
- 2019-03-26 US US16/364,763 patent/US20190276848A1/en not_active Abandoned
-
2021
- 2021-04-30 JP JP2021077161A patent/JP2021138702A/ja active Pending
-
2022
- 2022-11-08 US US18/053,407 patent/US20230332179A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531471A5 (enExample) | ||
| CN115023242B (zh) | 腺相关病毒载体变体 | |
| JP7374119B2 (ja) | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| JP7452953B2 (ja) | １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法 | |
| CN110606874B (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
| KR20240161976A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| KR20250025387A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| US20240067984A1 (en) | Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases | |
| KR20230051208A (ko) | 신규 aav 캡시드 및 이를 함유하는 조성물 | |
| JP2022531809A (ja) | ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法 | |
| WO2024006741A1 (en) | Aav capsid variants and uses thereof | |
| WO2024011112A1 (en) | Aav capsid variants and uses thereof | |
| WO2025038430A1 (en) | Aav capsid variants and uses thereof | |
| CN119403823A (zh) | 具有增强的肌肉转导效率的肽修饰的aav衣壳 | |
| WO2024226790A1 (en) | Aav capsid variants and uses thereof | |
| EP4504952A1 (en) | Compositions and methods for muscle disorders | |
| CN119677545A (zh) | 用于治疗神经系统疾病的组合物 | |
| RU2742435C2 (ru) | Композиции промоторов | |
| WO2023288325A2 (en) | Recombinant reelin gene therapy | |
| WO2024154102A1 (en) | Compositions and methods for administration of therapeutic and diagnostic agents to the central nervous system |